NCI-H1650 Xenograft Model Service for NSCLC

The NCI-H1650 xenograft model serves as a clinically relevant preclinical platform for studying EGFR-mutant non-small cell lung cancer (NSCLC) with intrinsic resistance phenotypes, enabling researchers to investigate tumor growth dynamics, evaluate combination therapeutic strategies, and dissect resistance mechanisms in a physiologically faithful immunodeficient host. Alfa Cytology provides comprehensive NCI-H1650 xenograft model services supported by authenticated cell stocks, rigorous quality assurance, and customizable endpoint analyses to advance your preclinical oncology programs from target validation to lead optimization.

Overview of NCI-H1650 Xenograft Model for NSCLC

The NCI-H1650 cell line was established from a pleural effusion specimen of a 27-year-old male patient with bronchioloalveolar carcinoma, a subtype of lung adenocarcinoma. Genetically, this line harbors a sensitizing EGFR exon 19 deletion (E746-A750del), yet it exhibits primary resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib—a phenotype attributed to concurrent PTEN loss and sustained Akt phosphorylation that bypasses EGFR blockade. This unique resistance profile makes NCI-H1650 an exceptional model for studying intrinsic TKI resistance mechanisms and for preclinical testing of next-generation therapeutic approaches including combination regimens, irreversible EGFR inhibitors, and pathway-directed interventions.

Fig 1. KIS overexpression enhanced NCI-H1650 cell proliferation, migration, invasion and β-catenin signaling via ID1, while ID1 knockdown abrogated these effects, providing the mechanistic basis for KIS-driven NCI-H1650 xenograft growth. (Chang, Jing-Xia, et al., 2024)

In immunodeficient murine hosts, NCI-H1650 cells form reproducible subcutaneous tumors with consistent take rates and moderate growth kinetics, supporting longitudinal tumor volume monitoring and pharmacodynamic sampling. The xenograft model has been extensively applied to evaluate the efficacy of multi-targeted kinase inhibitors, Hsp90 blockers, anti-EGFR antibody-drug conjugates, and autophagy modulators in combination with EGFR-directed agents. Endpoint tumor tissues are amenable to immunohistochemistry, Western blotting, RNA sequencing, and flow cytometric analysis, providing multi-layered mechanistic insights that bridge in vitro findings to in vivo therapeutic outcomes.

Cell Line Information: NCI-H1650

NCI-H1650 is a human lung adenocarcinoma cell line with bronchioloalveolar differentiation features, derived from a metastatic pleural effusion. The line carries a sensitizing EGFR mutation yet displays intrinsic resistance to first-generation EGFR-TKIs, offering a distinctive preclinical model for resistance mechanism studies. The following table summarizes the key biological and technical attributes of the NCI-H1650 cell line relevant to xenograft model development.

Our Services

Alfa Cytology delivers end-to-end NCI-H1650 xenograft model services tailored to your preclinical research objectives. Our scientific team manages every stage—from authenticated cell banking and health monitoring to tumor establishment, randomized dosing cohorts, compound administration, and multi-parameter endpoint analysis—ensuring regulatory compliance, data integrity, and transparent reporting throughout your study.

Workflow of NCI-H1650 Xenograft Model Construction

Construction of the NCI-H1650 xenograft model follows a systematic, quality-controlled workflow designed to ensure reproducible tumor growth, ethical compliance, and robust data generation. Each stage is executed under GLP-aligned standard operating procedures with complete documentation and batch traceability.

1. Cell Line Authentication and Expansion: NCI-H1650 cells are revived from authenticated cryopreserved master stocks and expanded under sterile conditions. Short tandem repeat (STR) profiling, mycoplasma testing, and viability assessment are performed to confirm identity and purity prior to inoculation.
2. Animal Preparation and Randomization: Immunodeficient mice are acclimated for a minimum of five days under controlled environmental conditions and then randomized into vehicle and treatment cohorts based on body weight. All animal procedures are conducted under institutional animal care and use committee (IACUC) approval.
3. Tumor Cell Inoculation: A suspension of 5 × 10⁶ NCI-H1650 cells in 100 µL of ice-cold PBS or PBS/Matrigel (1:1) is injected subcutaneously into the right flank of each mouse using a sterile 25-gauge needle. Orthotopic lung implantation may be performed upon request for studies requiring organ-specific tumor microenvironment interactions.
4. Tumor Monitoring and Measurement: Tumor dimensions are measured with digital calipers twice weekly beginning from the appearance of palpable masses. Tumor volume is calculated using the modified ellipsoid formula: length × (width)² / 2. Concurrent body weight recordings and clinical observations are documented.
5. Compound Administration and Dosing: Test articles are administered according to the study-specific regimen via oral gavage, intraperitoneal, intravenous, or subcutaneous routes. Vehicle control groups receive the equivalent formulation without active compound. Combination arms are configured as specified in the study protocol.
6. Endpoint Assessment and Tissue Collection: Mice are humanely euthanized upon reaching the predetermined endpoint—typically when tumor volume approaches 1,500 mm³ or at a fixed study duration. Tumors are excised, weighed, and partitioned for formalin-fixed paraffin-embedded (FFPE) histology, snap-frozen molecular analysis, and single-cell dissociation for flow cytometry.
7. Data Analysis and Reporting: Tumor growth curves, tumor growth inhibition (TGI) percentages, and statistical comparisons between treatment groups are generated using validated biostatistical software. A comprehensive study report including raw data, methodology, representative images, and mechanistic interpretation is delivered to the sponsor.

Fig 2. NCI-H1650 xenograft model construction workflow.

Case Study-NCI-H1650 Xenograft Model Development

In a recent preclinical engagement, the NCI-H1650 xenograft model was employed to evaluate the anti-tumor efficacy of a combination therapeutic regimen targeting both EGFR and compensatory resistance pathways. Following subcutaneous inoculation of 5 × 10⁶ cells into athymic nude mice, palpable tumors were established within 16 days with a take rate exceeding 90%. Animals were randomized into vehicle, monotherapy, and combination treatment arms once mean tumor volume reached approximately 200 mm³. Longitudinal monitoring revealed differential growth inhibition across cohorts, with combination-treated groups showing enhanced tumor suppression compared to single-agent controls. Endpoint analysis demonstrated modulation of downstream signaling markers including phosphorylated Akt and EGFR in tumor lysates, alongside reduced Ki-67 proliferative indices in responder groups. Histopathological examination confirmed preserved adenocarcinoma morphology and treatment-associated changes in tumor architecture. These preclinical findings supported the mechanistic rationale for advancing the combination strategy into subsequent development stages.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your NCI-H1650 xenograft studies provides access to a fully integrated preclinical infrastructure that combines scientific depth with operational excellence. Our service model is engineered to deliver actionable, high-fidelity data within competitive timelines.

• Authenticated cell repositories with routine STR profiling and mycoplasma screening to ensure genetic fidelity and experimental reproducibility.
• Customizable study designs encompassing subcutaneous, orthotopic, and metastatic model configurations to address diverse mechanistic questions.
• Real-time tumor growth tracking via digital calipers or optional non-invasive imaging modalities including bioluminescence and micro-CT upon request.
• Multi-layered endpoint analysis portfolios spanning histopathology, immunohistochemistry, Western blot, qPCR, RNA sequencing, and multiplex cytokine profiling.
• Dedicated project scientists delivering weekly progress updates, direct raw data access, and regulatory-compliant documentation packages.
• Accelerated study timelines with standard tumor establishment and treatment phases typically completed within 5–7 weeks from project initiation.

Contact Us

Ready to explore intrinsic resistance mechanisms and evaluate next-generation therapeutic strategies in EGFR-mutant NSCLC? Reach out to the Alfa Cytology scientific team today to discuss your study objectives, receive a customized proposal, and learn how our NCI-H1650 xenograft expertise can accelerate your preclinical pipeline. Contact us now to schedule a consultation and advance your program with robust, reproducible data.

For research use only. Not intended for any clinical use.